NEW YORK (GenomeWeb News) — Whatman today said it will provide DNA collection kits based on its FTA elute technology to an international prostate cancer pharmacogenotyping study that aims to uncover links between SNPs and drug efficacy, side-effects, or individual susceptibility to prostate cancer.
.
The study is part of the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy trial, also known as STAMPEDE.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.